A low osmolar, nonionic, iodinated contrast agent introduced in Canada in 1985, OMNIPAQUE has been used in more than 100 million patients worldwide. Its indications include a broad range of intravascular diagnostic procedures such as coronary angiography, spinal cord imaging, and body cavity procedures including shoulder and knee joints. OMNIPAQUE is approved for use in adults and children, and is available in a variety of packagings that meet the needs of safety, convenience, and cost efficiency.

All nonionic, iodinated contrast media currently available inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary to minimize thromboembolic events.